Previous Article | Next Article 
Journal of Bacteriology, January 2000, p. 311-319, Vol. 182, No. 2
0021-9193/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The PspA Protein of Escherichia coli Is
a Negative Regulator of
54-Dependent
Transcription
Jonathan
Dworkin,*
Goran
Jovanovic,
and
Peter
Model
Laboratory of Genetics, The Rockefeller
University, New York, New York 10021
Received 28 May 1999/Accepted 27 October 1999
 |
ABSTRACT |
In Eubacteria, expression of genes transcribed by an
RNA polymerase holoenzyme containing the alternate sigma factor
54 is positively regulated by proteins belonging to the
family of enhancer-binding proteins (EBPs). These proteins bind to
upstream activation sequences and are required for the initiation of
transcription at the
54-dependent promoters. They are
typically inactive until modified in their N-terminal regulatory domain
either by specific phosphorylation or by the binding of a small
effector molecule. EBPs lacking this domain, such as the PspF activator
of the
54-dependent pspA promoter, are
constitutively active. We describe here the in vivo and in vitro
properties of the PspA protein of Escherichia coli, which
negatively regulates expression of the pspA promoter
without binding DNA directly.
 |
INTRODUCTION |
Infection of Escherichia
coli with filamentous bacteriophage f1 results in the strong and
specific induction of the pspABCDE operon. This
operon contains five open reading frames, of which at least
four (pspA, -B, -C, and -E)
code for expressed proteins. Following cloning of the
pspABCDE operon, deletion analysis suggested that
the pspA gene encoded a protein which negatively regulated expression of the operon (7). Later experiments
demonstrated that the PspA protein, when transcribed from a
heterologous promoter, was sufficient to negatively regulate expression
of the operon in trans and that the absence of
full-length PspA in vivo resulted in constitutive high-level expression
of a mutant, truncated PspA protein, independent of the presence of any
other psp proteins (44). Further, the inability
of a frameshifted mutant PspA to inhibit psp expression
indicates that it is the protein that is responsible for inhibition.
Transcription of the psp operon is dependent on an
RNA polymerase (RNAP) holoenzyme containing the alternate sigma factor
54 (13, 44). Like that of other
54-dependent genes, transcription of pspA
requires activation by a protein, in this case PspF, which belongs to
the family of enhancer-binding proteins (EBPs) (13, 22).
Through an ATP hydrolysis-dependent mechanism, these proteins convert
the closed complex formed by
54 and RNAP at the promoter
into an open complex permissive for initiation (28). This
conversion is the result of DNA loop-mediated, protein-protein
contacts between the EBP and the
and
54 subunits of
the RNAP holoenzyme (31). Typically, EBPs are inactive until they are modified in their N-terminal domain either by binding an
effector molecule (e.g., xylene for XylR [15]) or
through a specific phosphorylation event (e.g., phosphorylation of
Asp54 of NRI by NRII [37]). By
contrast, PspF lacks this entire domain (as do the HrpR and HrpS
proteins of Pseudomonas syringae [48]) and
is constitutively active both in vivo and in vitro (22). In
addition, PspF autoregulates its own expression by binding to sites
overlapping its promoter, and its levels are constant in the presence
or absence of inducing stimuli (19). Thus, regulation of
pspA transcription cannot occur through the EBP modification pathway used by other
54-dependent systems. Since the in
vivo analysis of PspA demonstrated that it is required for this
negative regulation, we studied the action of PspA in vitro.
The pspA gene encodes the 25.5-kDa PspA protein that,
according to Chou-Fasman analysis (10), contains four long
-helices. Analysis of the protein sequence with the Macstripe
program (26), based on the Lupas algorithm (34),
strongly predicts that these helices will form a coiled coil comprising
nearly the entire length of the protein. Proteins with coiled-coiled
regions as extensive as that of PspA are relatively unusual in
prokaryotes, with the TlpA protein of Salmonella enterica
serovar Typhimurium providing one notable counterexample
(27). While PspA does not contain sequences characteristic
of integral inner membrane proteins (12), approximately 50%
of the total cellular PspA is associated with the inner membrane of
E. coli, and PspA is thus considered a peripheral membrane
protein (6). The lack of any obvious DNA-binding motif and
its acidic pI (5.56) suggests that PspA is not likely to bind DNA.
Three homologs of PspA have been identified: the SCYCSLRD protein
from the cyanobacterium Synechocystis sp. strain PCC6803 (23), the cold-shock-induced PspB protein from
Bacillus subtilis (16), and the IM30 protein of
pea chloroplasts (33). The IM30 protein is localized to both
of the envelope membranes and the thylakoid membrane of the
chloroplast; however, little else is known about it or any of the other
PspA homologs.
In addition to its roles in psp regulation, PspA appears to
participate in several aspects of cellular physiology. PspA is a major
component of the limited protein synthesis that occurs in late
stationary phase, and cells which lack pspA have reduced viability under alkaline conditions as well as in late stationary phase (45). PspA also appears to aid in the maintenance of
the proton motive force under stress conditions (25)
and can stimulate the export of secreted proteins (24).
Whether these seemingly disparate phenotypes reflect a common role for
PspA remains unclear. We chose, however, to focus on the mechanism of
PspA autoregulation, and we describe here experiments directed at
elucidating this mechanism.
 |
MATERIALS AND METHODS |
Plasmid and bacterial strain construction.
Bacterial strains
and plasmids used are listed in Table
1. Plasmid pJD40 was constructed with
primers JD88 (5'-GGCTCTGCAGAGATCTGATTGAAGAATCAACA) and
JD90 (5'-GGCTGAATTCACCTTAACTTAATGATTTTTAC) in a PCR
with Pfu polymerase (Stratagene) and pMJ3 (22) as
the template. The PCR product was digested with PstI and
EcoRI and ligated into the PstI and
EcoRI sites of pBR322. pJD42 was constructed with primers JD54 (5'-GGCTGGTACCTAGCGAGTTCATCAAGAAATA) and JD87
(5'-GGCTAAGCTTCGGAATAGCCAGAAATAGCG) in a PCR with
Pfu polymerase and pBRPS-1 (7) as the template. The PCR product was digested with BglII and
HindIII and ligated into the BamHI and
HindIII sites of pGZ119EH (32). pJD23 was generated with primers JD91 (5'-GGCTGTCGACCGGTATTTTTTCTCGCTTTGC) and JD87 in a PCR with Pfu polymerase and pJD42 as the
template. The PCR product was digested with SalI and
ScaI and ligated to the SalI and EcoRV
sites of plasmid pJH391 (18). pJD25 was generated by
ligating the 1.3-kb PstI fragment containing the
cat gene from pSKS114 into the PstI site of
pJD23. pJD26 was constructed by ligating the same 1.3-kb
PstI fragment into the PstI site of pJLB24. pJD43
was constructed by using primers JD76
(5'-GGCTACGCATATGGGTATTTTTTCTCGCTTTGCC) and JD78
(5'-GGCTGGATCCTTATTGATTGTCTTGCTTCATTTT) in a PCR with Pfu polymerase and pPS-1 (7) as the template. The
PCR product was digested with NdeI and BamHI
and ligated to pET15b (Novagen) digested with NdeI and
BamHI. pJD31 was constructed with primers JD50
(5'-GGCTGAATTCTAGCGAGTTCATCAAGAAATA) and JD51
(5'-GGCTGGATCCAATGTTGTCCTCTTGATTTCT) in a PCR with
Taq polymerase and pPS-1 as the template. The PCR product
was digested with BamHI and EcoRI and ligated to
plasmid pRS415 (43) digested with BamHI and
EcoRI. pJD42 was constructed with primers JD54 and JD87 in a
PCR with Pfu polymerase and pBRPS-1 (7) as the
template. The PCR product was digested with BglII and
HindIII and ligated to pGZ119EH digested with
BamHI and HindIII. pJD45 was constructed by
digesting pBRPS-1 with EcoRV and SphI and
ligating the blunt ends, which resulted in the loss of the BamHI site. The plasmid was then digested with
SnaBI, which removed a fragment containing the
pspF, -A, -B, and -C genes,
and a BamHI linker was inserted. The BamHI
fragment of pSKS101 (9) containing the kan gene
was then inserted into the BamHI site created by the linker.
The

psp3 phage that carries a
pspA-lacZ fusion was
generated by growing the

B305 phage (
3) that contains the
carboxy-terminal
coding sequences of the
lacZ and
bla genes on a strain carrying
the Amp
r plasmid
pJD31. Transfer of
pspA-lacZ to the phage was signaled
by
the reconstitution of the functional
lacZ and
bla
genes. Strains
were made lysogenic for

psp3 by conventional methods
(
42).
Strain JD50 was selected from K1342 (
lacIq
lacZ
M15
zah::Tn
10
Tet
s) by use of the fusaric acid technique (
5).
P1 transduction
from strain J134 (
44)
(
pspABC::
kan) into JD50 yielded JD54.
JD59 was generated by P1 transduction from strain K1527 (
22)
(
pspF877::
tet). The
pspFABC mutation was introduced by homologous
recombination (
46) into strain MC4100F
+,
yielding strain JD61. Plasmid pJD45 was linearized with
NcoI
and transformed into strain JC7623, a
recB recC sbcB mutant.
DNA
made from a Kan
r transformant was examined by
Taq polymerase-based PCR with the
primers JABR6 and
IR1070Bam (
22), which are complementary to
sequences
in the
pspA and
pspF genes, respectively.
Additionally,
transduction of this mutation into a strain containing
the

psp3
lysogen resulted in a severe reduction in
pspA-lacZ expression
(data not shown). Plasmid pJD41
containing the
pspF gene was transformed
into this strain,
which resulted in

-galactosidase levels higher
than that of a
wild-type strain, suggesting that PspA was absent
(data not shown).
Transformation of a second plasmid, pJD42, containing
pspA
under
lac control reduced this increased level of
pspA-lacZ expression, thus confirming that the strain lacked
both the
pspA and
pspF genes (data not
shown).
-Galactosidase assay.
All measurements of
-galactosidase activity were conducted according to the established
protocol (35).
In vitro transcription assay.
The protocol used for in vitro
transcription was as described previously (13), unless
explicitly noted in the figure legends. Purification of PspF and PspF
with a deletion of the helix-turn-helix (PspF
HTH) was as described
previously (21).
Purification of PspA.
Strain K1462 (
DE3)/pJD43 was grown
at 37°C with aeration in 250 ml of FB (per liter, 25 g of
tryptone [Difco], 7.5 g of yeast extract [Difco], 6 g of
NaCl, 1 g of glucose, 50 ml of 1 M Tris-Cl [pH 7.6]) from a
dilution of 5 ml of a culture grown overnight in FB until an optical
density at 660 nm of 0.4 was reached. Then, 2 mM IPTG
(isopropyl-
-D-thiogalactopyranoside) was added and the
cells were allowed to grow 5 h more at 37°C with high aeration. The cells were chilled and centrifuged at 5,000 × g
for 10 min at 4°C. The supernatant was removed, and the pellet was
either resuspended as described below or stored at
20°C.
All subsequent steps were done at 0 to 4°C. The pellet was
resuspended in 2.5 ml of cold sonication buffer (100 mM Tris-Cl
[pH
7.5], 50 mM NaCl). The suspension was sonicated (three times,
20 s at setting 60, Sonicator cell disruptor) and was then centrifuged
for
8 min at 15,000 ×
g. The supernatant was removed, and
the
pellet was homogenized and resuspended in 3 ml of buffer A (100
mM
Tris-Cl [pH 7.5], 300 mM NaCl), to which was added 0.2 ml of
a
freshly made 20% solution of CHAPS
{3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate}
(in
glass-distilled water; Sigma) and 0.2 ml of 5 M NaCl, giving
final
concentrations of 1.1% CHAPS and 0.6 M NaCl. The suspension
was rocked
on a Nutator platform for 120 min and then centrifuged
at
15,000 ×
g for 6 min. The supernatant was removed and
added
to 0.5 ml of Talon resin (Clontech) which had been washed twice
with 5 ml of buffer A. The mixture was nutated for 120 min and
then
placed into a 5-ml gravity column (Clontech) and allowed
to settle for
30 min. The supernatant was allowed to flow through,
and the column was
washed with 5 ml of a solution containing 100
mM Tris-Cl [pH 7.5],
300 mM NaCl, and 10 mM imidazole. Protein
was eluted with fractions of
100 mM Tris-Cl (pH 7.5)-60 mM NaCl-100
mM imidazole. Individual
fractions were dialyzed against three
changes (350 ml each) of 20 mM
Tris-Cl (pH 7.5)-60 mM NaCl, glycerol
was added to 20%, and the
fractions were stored at

70°C.
Purification was assessed by sodium dodecyl sulfate-10%
polyacrylamide gel electrophoresis (
29), followed by
staining with
Coomassie brilliant blue as described previously
(
41). Protein
concentrations were determined with a DC
protein assay kit (Bio-Rad).
Gel mobility shift assay.
The 260 fragment (260 bp) contains
the entire psp promoter region, including sequences from
188 to +72 relative to the start site of pspA
transcription (20). The gel mobility shift assay using
either cell extract from a strain overproducing PspF or purified PspA
protein at specified concentrations was performed with 2 ng of the 260 fragment as described previously (20).
 |
RESULTS |
PspA acts in vivo as a negative regulator of pspA
transcription.
Induction of the psp operon is
accompanied by an increase in the amount of
pspABCDE-specific mRNA (7), but neither that study nor the subsequent in vivo study of PspA (44)
demonstrated that PspA acts directly on transcription. All previous
assays of PspA function had relied on measurement of PspA protein
levels and thus could not exclude posttranscriptional regulation. We fused the pspA promoter with the lacZ gene (with
the lac ribosome-binding site) carried on a lambda lysogen
to assay pspA promoter activity. In a wild-type
psp+ strain, lacZ expression was
quite modest from the pspA promoter, but in a
pspABC deletion mutant, there was a 50-fold increase in
lacZ expression (Table 2).
Production of PspA from a plasmid containing pspA under
lac control repressed expression of the fusion (Table 2) but
had no effect on expression of lacZ under the control of its
own promoter (data not shown). This experiment shows that PspA is
sufficient to inhibit pspA transcription. Further, since the
fusion contains psp-specific sequences only up to +30 relative to the start site of transcription (and thus lacks the pspA ribosome-binding site and the pspA gene),
the negative regulation does not require downstream sequences.
We then addressed the issue of whether PspA affects the
ability of PspF to bind DNA or whether PspA might act by
affecting
the DNA geometry of the
pspA promoter region
as does the Nac protein
of
Klebsiella aerogenes at the
nac promoter (
14). To test this
possibility, the
effect of PspA on PspF

HTH was examined. This
protein, encoded
by
pspF877, lacks the C-terminal 31 amino acids
of PspF that
comprise nearly the entire helix-turn-helix motif
thought to constitute
the DNA-binding domain. While it does not
bind DNA (
21),
PspF

HTH can still activate
pspA transcription
when
present at high concentrations (
13).
pspA-lacZ
expression
in a
pspF877 strain was reduced to almost
background levels (Table
2); this reduction may simply have been
the result of the low
level of activation by the PspF

HTH
protein in single copy or
may reflect both the weakened transcriptional
activation by PspF

HTH
and repression by
PspA.
To distinguish between these two possibilities, a plasmid containing
the
pspF877(PspF

HTH) gene (under the control of its
native promoter) was introduced into a strain containing a
pspFABC deletion but lacking such a plasmid. In this strain,
lacZ expression
from the
pspA-lacZ construct was
very low (Table
2) and was not
further reduced by introduction of a
plasmid expressing PspA protein
under
lac control.
Introduction of a plasmid bearing
pspF877 into
the
pspFABC strain increased
lacZ expression
20-fold (Table
2),
and this increase was repressed by the presence and
induction
of a compatible plasmid containing
pspA under
lac control (Table
2). Thus, PspA negatively regulates
transcription even when the
activator does not bind
DNA.
PspA acts as a dimer in vivo.
Given that coiled-coiled
proteins form dimers or higher-order oligomers (1), we
asked whether this was true of PspA. A system developed to assay
the sequence requirements for the leucine zipper of the
Saccharomyces cerevisiae transcriptional activator GCN4
offers a useful method to assay protein dimerization in vivo (18). The system takes advantage of the observation that the N-terminal DNA-binding domain of the
repressor dimerizes
inefficiently and requires a separate C-terminal dimerization domain in
order to bind to its operator and effect repression. We constructed a
fusion of this N-terminal domain to PspA and tested its ability to
repress a
pR-lacZ fusion carried
on a lambda lysogen.
The background expression of the fusion was repressed by either the
wild-type

repressor or the

repressor-GCN4 fusion (Table
3). While PspA alone had no effect on
expression of the fusion,
the

repressor-PspA fusion repressed
strongly (Table
3). This
result suggests that PspA is able to mediate
dimerization of two

repressor N-terminal domains through the
formation of a PspA
homodimer. Additionally, analysis of purified PspA
on nondenaturing
gels suggests that it forms dimers (and perhaps
higher-order multimers
[G. Jovanovic, unpublished data]). We also
asked whether the
repressor-PspA fusion could negatively
regulate expression from
the
pspA (as distinct from the
pR) promoter. Use of a strain
carrying the
pspA-lacZ promoter fusion together with the
pspABC deletion showed that the

repressor-PspA fusion
negatively regulates
pspA transcription, albeit slightly
less effectively than wild-type
PspA (Table
3). Thus, even though PspA
is fused to this heterologous
DNA-binding domain, it remains active.
Purification of PspA.
We purified PspA by His6
tag-Ni2+ affinity chromatography (39). The
pspA gene was cloned downstream and in frame with a DNA sequence coding for His6 in the pET15B expression vector.
Before purification was initiated, the activity of
His6-PspA as a negative regulator of pspA
transcription was tested by expressing the plasmid in a strain
containing a pspA-lacZ reporter and demonstrating that it
was as effective as a plasmid expressing wild-type PspA (data not shown).
Previous characterization of PspA demonstrated that it was recovered
approximately equally in the cytoplasmic and membrane
fractions
(
6). Initial efforts aimed at purification starting
with the
soluble fraction obtained following cell lysis, sonication,
centrifugation, and elution from the Talon resin-containing column
yielded small quantities of PspA relative to the total cellular
content. Given the original observations of the subcellular
localization
of PspA, it seemed possible that PspA would partition with
the
insoluble fraction because of its affinity for the hydrophobic
components in the initial postsonication pellet. Several detergents
were assayed for their ability to release PspA from the insoluble
fraction. While the nonionic detergents like Triton X-100 were
not
particularly effective, the zwitterionic detergent CHAPS and,
to a
somewhat greater extent, the ionic detergents deoxycholate
and sodium
Sarkosyl released most of the PspA (data not shown).
CHAPS was chosen
because up to 2% CHAPS did not interfere with
binding of
His
6-PspA to the Talon
resin.
The overexpressed protein was largely in the detergent supernatant
fraction (S2) rather than in the soluble fraction (S1)
(Fig.
1). The S2 fraction contained
approximately 25% of the total
PspA. Following incubation of S2 with
the Talon resin, most of
the His
6-PspA was bound to the
resin, since there was little in
the flowthrough from the gravity
column. It was specifically bound,
because a wash with a low
concentration of imidazole (10 mM) released
little
His
6-PspA protein but substantial amounts of other
proteins.
Results of elution with successive fractions of 0.1 M
imidazole
are presented in the right panel of Fig.
1. Fractions 4, 5, 6,
and 7 show His
6-PspA in comparatively pure form. The
majority
of the His
6-PspA which was bound to the resin was
released by
elution with imidazole. These fractions were dialyzed to
remove
the imidazole (which inhibits transcription), pooled, and stored
at

70°C in storage buffer (20 mM Tris-Cl [pH 7.5], 60 nM NaCl,
20% glycerol), where the protein appeared to be stable for more
than 2 weeks.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 1.
Purification of PspA. The left-hand panel illustrates
the steps in the purification of His6-PspA as described in
Materials and Methods. Portions of each step in the purification were
analyzed by sodium dodecyl sulfate-10% polyacrylamide gel
electrophoresis and stained with Coomassie brilliant blue. Lanes
(percentages in parentheses are the portions of the step that were
loaded): M, markers (from the bottom, 21, 30, 46, 66, and 97.4 kDa); P,
preinduction K1462.pJD43; I, postinduction K1462.pJD43 (0.06%); S1,
soluble fraction (0.1%); S2, soluble fraction following solubilization
of the pellet with CHAPS-NaCl (0.1%); FT, flowthrough from the gravity
column (0.1%); W, 10 mM imidazole wash (0.2%). The right-hand panel
shows fractions from the elution with 100 mM imidazole in order of
elution (2% of each fraction was loaded).
|
|
In vitro activity of PspA.
In vitro transcription assays
containing purified components, including RNAP holoenzyme and a
specific DNA template, demonstrated that His6-PspA has a
strong negative effect on transcription from the
54-dependent pspA promoter (pspA)
but no effect on the
70-dependent tac
promoter (Fig. 2A). A sample of
His6-PspA was boiled for 10 min before being added to the
pspA in vitro transcription reaction mixture. Surprisingly,
this treatment reduced the inhibitory activity only approximately
twofold; by contrast, incubating the protein on ice for 3 days resulted
in a near total loss of function (data not shown). A mock purification
from the same strain used to purify His6-PspA, but
containing a plasmid lacking the his6-pspA clone, had no effect on pspA transcription, whereas a
purification conducted in parallel with the plasmid that overproduces
His6-PspA yielded an activity with the inhibitory effect
(Fig. 2B).

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 2.
Controls for PspA inhibition of pspA
transcription. (A) In vitro transcription reaction mixtures contained
either supercoiled pJD10 (wild-type pspA promoter) or
supercoiled pGZ119EH (tac promoter). PspF was included at 4 nM in lanes 1 and 2. 54 and core RNAP were omitted from
the reaction mixture, and 70-RNAP holoenzyme was
included instead at 13 nM. PspA (300 nM) was included in lanes 2 and 4. (B) In vitro transcription reaction mixtures contained supercoiled
pJD10 (wild-type pspA promoter) and PspF at 4 nM. PspA (300 nM) was included in lane 2. Lane 3 contains a fraction from a
purification of a strain carrying only the expression vector (see the
text for more details).
|
|
Since in vivo experiments demonstrated that PspA inhibits
PspF

HTH-dependent activation of
pspA (Table
2),
His
6-PspA was
assayed in in vitro
pspA
transcription reaction mixtures containing
purified PspF

HTH.
Although PspF

HTH was much less effective in
stimulating
transcription from the
pspA promoter than PspF, it
was
inhibited by the same concentration of PspA (8-fold) (Fig.
3A, lanes 3 and 4) to the same extent as
PspF (13-fold) (Fig.
3A, lanes 5 and 6).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
PspA activity in vitro determined after inhibition of
PspF HTH- and NRI-dependent activation of transcription.
(A) In vitro transcription reactions were performed as described in
Materials and Methods except that all components were incubated
together at 37°C for 10 min without the template and then the
template (15 nM) was added with [ -32P]CTP. The
reaction then proceeded at 37°C for 10 min before addition of cold
CTP. Templates were either the wild type (wt) (lanes 3 to 6, supercoiled pJD10, wt pspA promoter) or a UAS mutant
(lanes 1 and 2, supercoiled pJD12, pspA promoter without the
UAS I and II sites). PspA (300 nM) was in lanes 2, 4, and 6; PspF (4 nM) was in lanes 1, 2, 5, and 6; and PspF HTH (70 nM) was in lanes 3 and 4. The arbitrary units of quantified pspA RNA
transcripts were as follows: 3,110 (lane 1), 410 (lane 2), 105 (lane
3), 13 (lane 4), 5,784 (lane 5), and 434 (lane 6). (B) Reactions were
performed as described for panel A with either supercoiled pJD10 (lanes
1 and 2; wt pspA promoter) or supercoiled pFC50 (lanes 3 and
4; glnH promoter). PspA (300 nM) was in lanes 2 and 4; PspF
(4 nM) was in lanes 1 and 2; and NRI (30 nM, also 30 nM
NRII) was in lanes 3 and 4. The arbitrary units of
quantified pspA RNA transcripts were as follows: 7,785 (lane 1), 613 (lane 2), (glnH RNA transcript) 5,431 (lane
3), and (glnH RNA transcript) 486 (lane 4). HTH,
helix-turn-helix.
|
|
PspA does not bind DNA.
No property of PspA, including its
sequence, suggests that it is a DNA-binding protein. When tested
explicitly by a gel shift assay, PspA did not affect the mobility of a
linear DNA fragment containing sequences (
188 to +72) spanning the
pspA promoter (Fig. 4, lanes 6 to 10). By contrast, extract from cells overexpressing PspF shifted
this fragment (Fig. 4, lanes 2 to 4) as has been reported previously
(20). Additionally, since PspF
HTH does not bind DNA in
vitro (21), it is therefore unlikely that PspA-dependent inhibition of pspA is mediated by binding of PspA to DNA in
the promoter region containing the upstream activation sequences
(UASs). Further evidence for this interpretation comes from the
observation that His6-PspA inhibition of pspA
transcription was nearly as effective when the template lacked the UASs
(Fig. 3A, lanes 1 and 2) as when the template was the wild type (lanes
5 and 6). Also consistent is the observation (see below) that PspA
inhibits transcription at another
54-dependent promoter
(glnA) containing UASs completely different from those of
pspA.

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 4.
PspA does not bind DNA in the pspA promoter
region. The 260 fragment containing sequences from 188 to +72
relative to the start site of pspA transcription
(20) was used in a gel mobility shift assay using either
crude cell extract from a strain overproducing PspF (lanes 2 to 4),
purified PspA protein (lanes 6 to 9), or no added protein (lanes 1 and
5). In addition to 2 ng of 32P-labeled 260 fragment, each
lane contained the following. Lane 2, 1 µl of crude cell extract;
lane 3, 200 ng of nonspecific competitor [poly(dI-dC)] and 1 µl of
crude cell extract; lane 4, 400 ng of nonspecific competitor and 2 µl
of crude cell extract; lane 5, 400 ng of nonspecific competitor, 2 µl
of crude cell extract, and 300 ng of specific competitor (unlabeled 260 fragment); lane 6, 10 nM purified PspA; lane 7, 20 nM purified PspA;
lane 8, 50 nM purified PspA; lane 9, 100 nM purified PspA.
|
|
Specificity of PspA inhibition.
Since the promoter specificity
of activation by EBPs is thought to reside in the sequences of their
DNA-binding domains (36), the inhibition of
Psp
HTH-dependent pspA transcription suggests that PspA
may be active against other EBPs. That is, given that the PspF
HTH
protein is composed of only the central domain which contains the
residues involved in ATP hydrolysis as well as the catalysis of
open-complex formation, a protein able to inhibit PspF
HTH activation must interact either with this domain or
with its target, the RNAP holoenzyme. Since this central domain is highly conserved, a protein which interacts with PspF
HTH might interact with the central domains of other EBPs and inhibit
activation of transcription. In fact, NRI-dependent
(11-fold) (Fig. 3B, lanes 3 and 4) activation of the glnH
promoter is inhibited by His6-PspA to an extent similar to
that of PspF-dependent activation of the pspA promoter
(13-fold) (Fig. 3B, lanes 1 and 2). The in vivo significance of this
inhibition of a heterologous EBP by PspA should be the subject of
future investigations.
Titration of PspA inhibition of pspA
transcription.
Titration of His6-PspA activity in
inhibiting pspA (Fig. 5)
demonstrated that, at a concentration of 300 nM, His6-PspA
almost entirely eliminates PspF-dependent pspA-specific
transcription but that this concentration has little effect on
70-dependent tac transcription (Fig. 2A,
lanes 3 and 4). The midpoint of this titration (~100 nM) suggests
that the interaction between PspA and its target protein is relatively
weak. Also, this concentration is relatively high when compared to the
concentrations of PspF (4 nM) and
54 (45 nM). If
His6-PspA targets some aspect of the interaction between
PspF and
54, then as a non-DNA-binding protein, it is at
a disadvantage because the concentrations of PspF and
54
relative to each other when both are bound to the DNA are higher than
their simple solution concentrations.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Titration of PspA inhibition of pspA
transcription. (A) In vitro transcription reactions were performed as
described in Materials and Methods with supercoiled pJD10 (wild-type
pspA promoter) except that all components were incubated
together at 37°C for 10 min without the template, and then the
template (15 nM) was added with [ -32P]CTP. The
reaction then proceeded at 37°C for 10 min before addition of cold
CTP. PspA was added in the concentration shown under each lane. PspF
was added at 4 nM. (B) Quantification was carried out as described in
Materials and Methods and was plotted as the quantity of the
pspA-specific transcript (in arbitrary transcription units)
against the concentration of PspA.
|
|
Mechanism of PspA inhibition.
In view of the hypothesis that
PspA acts by binding either
54 or PspF, and by
preventing their interaction, we modified the in vitro transcription
protocol. Since the interaction of DNA-binding proteins is facilitated
by DNA, we incubated all protein components in the absence of DNA. This
change in experimental protocol had little effect on the ability of
PspA to inhibit pspA-specific transcription (Fig.
6A, lanes 1 and 2). We then increased
the concentrations of various components of the reaction.
Increasing the concentration of either the DNA template (Fig. 6A, lane
5) or
54 (lane 7) fourfold (compared to that in Fig. 6A,
lanes 1 and 2) was not stimulatory for pspA transcription;
thus, neither factor is limiting. Addition of an excess of PspF (lane
3) stimulated transcription both in the presence and in the absence of
PspA. A decrease in
54 levels to below saturation had no
effect on PspA inhibition of pspA transcription (data
not shown).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
Analysis of the PspA target in inhibition of
pspA transcription. (A) In vitro transcription reactions
used supercoiled pJD10 (wild-type pspA promoter) except that
all components were incubated together at 37°C for 10 min without the
template, and then the template (15 nM) was added with
[ -32P]CTP. The reaction then proceeded at 37°C for
10 min before addition of cold CTP. PspA (300 nM) was present in lanes
2, 4, 6, and 8. PspF was present at 4 nM in all lanes except for lanes
3 and 4, where it was present at 16 nM. Also, in lanes 5 and 6, the
template was present at 60 nM; in lanes 7 and 8, 54 was
present at 172 nM. The pspA RNA transcripts were quantified
(in arbitrary units) as follows: 6,810 (lane 1), 731 (lane 2), 15,160 (lane 3), 2,320 (lane 4), 3,140 (lane 5), 419 (lane 6), 2,958 (lane 7),
and 418 (lane 8). (B) In vitro transcription reactions were performed
as described for panel A with pJD10 (wild-type pspA
promoter) except that in lanes 1 and 2, PspF was added at the same time
as the template and the [ -32P]CTP. PspA (300 nM) was
present in lanes 2 and 4; PspF was present at 4 nM. The pspA
RNA transcripts were quantified (in arbitrary units) as follows: 4,601 (lane 1), 2,025 (lane 2), 3,322 (lane 3), and 406 (lane 4). preincub.,
preincubation.
|
|
Since the ratio of
pspA-specific transcripts in the presence
or absence of PspA was unaffected by the increased concentrations
of the reaction components, it seems unlikely that a simple
sequestration
mechanism involving tight binding and inactivation of any
of these
components is responsible for PspA's inhibitory function. The
simplest explanation for these results is that PspA binds to PspF
with
relatively low affinity. A second explanation, that most
of the added
PspA is inactive, is rendered unlikely by the observation
that the
ratio of
pspA transcription in the absence or presence
of
PspA did not change appreciably after the concentration of
PspF was
increased fourfold. If the apparent association constant
of ~100 nM
determined from the results shown in Fig.
5 is correct,
then under the
conditions used here, where the concentration of
PspA was 300 nM, an
increase in the concentration of PspF from
4 to 16 nM would be expected
to leave the extent of inhibition
essentially
unchanged.
We compared the effect on PspA inhibition of addition of PspF prior to
the addition of DNA (the same protocol as described
above) with the
effect of the addition of PspF simultaneously
with the DNA. In this
case, incubation of PspA with PspF before
addition of DNA (Fig.
6B,
lanes 3 and 4) showed a greater inhibition
of
pspA-specific
transcripts than addition of PspF at the same
time as the DNA (Fig.
6B,
lanes 1 and 2). Thus, PspF bound to
DNA and presumably able to interact
with the
54-RNAP holoenzyme complex is more resistant to
inhibition than
PspF free in
solution.
 |
DISCUSSION |
The dependence of transcriptional initiation by
54-RNAP on activation by an EBP suggests several
potential mechanisms of negative regulation. Typically, EBPs are
activated by modification of their N-terminal domains, so a mechanism
that prevents this modification from occurring would inhibit
activation. Alternatively, a protein might interact with the central
domain of the EBP that contains the residues essential for ATP
hydrolysis and for activation and directly inhibit one of these
catalytic activities. Finally, EBPs bound to the UAS must interact with
54-RNAP bound at the promoter, so a protein might
prevent this interaction either by binding to and/or modifying the
domains of the proteins that mediate this contact(s) or by blocking the
binding of the EBP to the UAS sequences.
Most
54-dependent promoters studied to date employ some
variation of the first mechanism. In contrast, the inhibitory NifL protein of Klebsiella pneumoniae, appears to act by
stoichiometric interaction with EBP NifA, as suggested by in vivo
experiments (17) and confirmed in vitro with NifL purified
from K. pneumoniae (4) or from Azotobacter
vinelandii (2). Interestingly, NifL acts to inhibit
activity of a NifA mutant lacking both the N-terminal and C-terminal
domains (4). This mutant retains NTPase activity, which is
not affected by NifL, suggesting that NifL acts to prevent interaction
between NifA and
54-RNAP. Since NifL does not inhibit
activation by other EBPs, including NtrC (2, 4, 30) and AnfA
(2), the target of this interaction presumably is NifA
rather than
54-RNAP.
PspF lacks an endogenous N-terminal domain and is constitutively active
in vivo and in vitro, suggesting that it is subject to an inhibitory
regulatory mechanism dependent on a second protein. Here we have
demonstrated that in vivo (Table 2) and in vitro (Fig. 2),
pspA transcription in the presence of PspF and
54-RNAP is subject to inhibition by PspA. This
inhibition is independent of the ability of PspF to bind DNA because
PspA inhibits PspF
HTH-dependent activation in vivo (Table 2) and in
vitro (Fig. 3). Thus, similarly to NifL, PspA must interfere with some
aspect of PspF function involving the central domain. However, unlike
NifL, PspA inhibits activation by another EBP, NRI (Fig.
3); thus, PspA must initially recognize and consequently inhibit a part
of the
54-RNAP activation pathway common to all EBPs. An
interesting question raised by this inhibition is whether induction of
PspA expression has any effect on other
54-dependent
promoters in vivo.
Also, unlike NifL, PspA is not active in near-unity, stoichiometric
concentrations with its target EBP (Fig. 5). The observation (Fig. 6A)
that a higher concentration of individual reaction components (e.g., PspF,
54, and DNA) failed to reduce the
magnitude of PspA inhibition is consistent with the interpretation
that the high-concentration requirement of PspA is real. Further, this
observation is not consistent with a model of PspA inhibition where
PspA binds to proteins with high affinity and thereby acts to sequester
them from participation in transcriptional activation, as is the case with anti-sigma factors (8).
PspA inhibition is enhanced when reaction conditions are such that PspA
and PspF can interact in the absence of DNA (Fig. 6B, lanes 3 and 4)
compared to in its presence (Fig. 6B, lanes 1 and 2). This result
suggests that incubation of PspA and PspF when PspF is not able to bind
DNA allows for an interaction essential for PspA inhibition. Since PspA
inhibits PspF
HTH-dependent transcription equally as well as
PspF-dependent transcription, DNA binding can not per se be the target
of PspA. EBPs form tetramers (40) and higher-order oligomers
on DNA (47), and it is thought that these ATP-dependent
structures (38) are necessary intermediates in the reaction
whereby the EBPs convert the
54-RNAP closed complex to
an open complex. This oligomerization is characteristic not only of
PspF but, interestingly, also of PspF
HTH, despite its inability to
bind DNA (21). Thus, PspA may target PspF monomers or dimers
and so a fourfold increase in PspF concentration in the presence of DNA
would yield mostly an increase in oligomer. Given the apparent
importance (and as yet incompletely understood role) of these oligomers
for the mechanism of transcriptional activation at
54-dependent promoters, this possibility should be
explored more fully in future experiments.
 |
ACKNOWLEDGMENTS |
We thank Alex Ninfa for NRI, NRII, and
54 proteins; Jim Hu for the N-terminal
repressor
fusion kit; and members of our laboratory for helpful discussions.
This work was supported by NSF grant MCB 93-16625. J.D. held an NSF
graduate fellowship and was supported by NIH training grant CA09673-19
and by a Norman and Rosita Winston Foundation fellowship.
 |
FOOTNOTES |
*
Corresponding author. Present address: Dept. of
Molecular and Cellular Biology, Harvard University, 16 Divinity
Ave., Cambridge, MA 02138. Phone: (617) 495-0532. Fax: (617)
496-4642. E-mail: dworkin2{at}fas.harvard.edu.
Present address: Department de Biochimie Medicale,
Centre Medical Universitaire, 1211 Geneva 4, Switzerland.
 |
REFERENCES |
| 1.
|
Adamson, J. G.,
N. E. Zhou, and R. S. Hodges.
1993.
Structure, function and application of the coiled-coil protein folding motif.
Curr. Opin. Biotechnol.
4:428-437[CrossRef][Medline].
|
| 2.
|
Austin, S.,
M. Buck,
W. Cannon,
T. Eydmann, and R. Dixon.
1994.
Purification and in vitro activities of the native nitrogen fixation control proteins NifA and NifL.
J. Bacteriol.
176:3460-3465[Abstract/Free Full Text].
|
| 3.
|
Baron, J., and R. A. Weisberg.
1992.
Mutations of the phage lambda nutL region that prevent the action of Nun, a site-specific transcription termination factor.
J. Bacteriol.
174:1983-1989[Abstract/Free Full Text].
|
| 4.
|
Berger, D. K.,
F. Narberhaus, and S. Kustu.
1994.
The isolated catalytic domain of NIFA, a bacterial enhancer-binding protein, activates transcription in vitro: activation is inhibited by NIFL.
Proc. Natl. Acad. Sci. USA
91:103-107[Abstract/Free Full Text].
|
| 5.
|
Bochner, B. R.,
H. C. Huang,
G. L. Schieven, and B. N. Ames.
1980.
Positive selection for loss of tetracycline resistance.
J. Bacteriol.
143:926-933[Abstract/Free Full Text].
|
| 6.
|
Brissette, J. L.,
M. Russel,
L. Weiner, and P. Model.
1990.
Phage shock protein, a stress protein of Escherichia coli.
Proc. Natl. Acad. Sci. USA
87:862-866[Abstract/Free Full Text].
|
| 7.
|
Brissette, J. L.,
L. Weiner,
T. L. Ripmaster, and P. Model.
1991.
Characterization and sequence of the Escherichia coli stress-induced psp operon.
J. Mol. Biol.
220:35-48[CrossRef][Medline].
|
| 8.
|
Brown, K. L., and K. T. Hughes.
1995.
The role of anti-sigma factors in gene regulation.
Mol. Microbiol.
16:397-404[CrossRef][Medline].
|
| 9.
|
Casadaban, M. J.,
J. Chou, and S. N. Cohen.
1980.
In vitro gene fusions that join an enzymatically active beta-galactosidase segment to amino-terminal fragments of exogenous proteins: Escherichia coli plasmid vectors for the detection and cloning of translational initiation signals.
J. Bacteriol.
143:971-980[Abstract/Free Full Text].
|
| 10.
|
Chou, P. Y., and G. D. Fasman.
1974.
Prediction of protein conformation.
Biochemistry
13:222-245[CrossRef][Medline].
|
| 11.
|
Claverie-Martin, F., and B. Magasanik.
1991.
Role of integration host factor in the regulation of the glnHp2 promoter of Escherichia coli.
Proc. Natl. Acad. Sci. USA
88:1631-1635[Abstract/Free Full Text].
|
| 12.
|
Cserzo, M.,
E. Wallin,
I. Simon,
G. von Heijne, and A. Elofsson.
1997.
Prediction of transmembrane alpha-helices in prokaryotic membrane proteins: the dense alignment surface method.
Protein Eng.
10:673-676[Abstract/Free Full Text].
|
| 13.
|
Dworkin, J.,
G. Jovanovic, and P. Model.
1997.
Role of upstream activation sequences and integration host factor in transcriptional activation by the constitutively active prokaryotic enhancer-binding protein PspF.
J. Mol. Biol.
273:377-388[CrossRef][Medline].
|
| 14.
|
Feng, J.,
T. J. Goss,
R. A. Bender, and A. J. Ninfa.
1995.
Repression of the Klebsiella aerogenes nac promoter.
J. Bacteriol.
177:5535-5538[Abstract/Free Full Text].
|
| 15.
|
Fernandez, S.,
V. de Lorenzo, and J. Perez-Martin.
1995.
Activation of the transcriptional regulator XylR of Pseudomonas putida by release of repression between functional domains.
Mol. Microbiol.
16:205-213[CrossRef][Medline].
|
| 16.
|
Graumann, P.,
K. Schroder,
R. Schmid, and M. A. Marahiel.
1996.
Cold shock stress-induced proteins in Bacillus subtilis.
J. Bacteriol.
178:4611-4619[Abstract/Free Full Text].
|
| 17.
|
Henderson, N.,
S. A. Austin, and R. A. Dixon.
1989.
Role of metal ions in negative regulation of nitrogen fixation by the nifL product from Klebsiella pneumoniae.
Mol. Gen. Genet.
216:484-491[CrossRef].
|
| 18.
|
Hu, J. C.,
E. K. O'Shea,
P. S. Kim, and R. T. Sauer.
1990.
Sequence requirements for coiled-coils: analysis with lambda repressor-GCN4 leucine zipper fusions.
Science
250:1400-1403[Abstract/Free Full Text].
|
| 19.
|
Jovanovic, G.,
J. Dworkin, and P. Model.
1997.
Autogenous control of PspF, the constitutively active enhancer-binding protein of Escherichia coli.
J. Bacteriol.
179:5232-5237[Abstract/Free Full Text].
|
| 20.
|
Jovanovic, G., and P. Model.
1997.
PspF and IHF bind cooperatively in the psp promoter-regulatory region of Escherichia coli.
Mol. Microbiol.
25:473-481[CrossRef][Medline].
|
| 21.
|
Jovanovic, G.,
J. Rakonjac, and P. Model.
1999.
In vivo and in vitro activities of the Escherichia coli 54 transcription activator, PspF, and its DNA-binding mutant, PspF HTH.
J. Mol. Biol.
285:469-483[CrossRef][Medline].
|
| 22.
|
Jovanovic, G.,
L. Weiner, and P. Model.
1996.
Identification, nucleotide sequence, and characterization of PspF, the transcriptional activator of the Escherichia coli stress-induced psp operon.
J. Bacteriol.
178:1936-1945[Abstract/Free Full Text].
|
| 23.
|
Kaneko, T.,
A. Tanaka,
S. Sato,
H. Kotani,
T. Sazuka,
N. Miyajima,
M. Sugiura, and S. Tabata.
1995.
Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis sp. strain PCC6803. I. Sequence features in the 1 Mb region from map positions 64% to 92% of the genome (supplement).
DNA Res.
2:191-198[CrossRef].
|
| 24.
|
Kleerebezem, M.,
W. Crielaard, and J. Tommassen.
1996.
Involvement of stress protein PspA (phage shock protein A) of Escherichia coli in maintenance of the protonmotive force under stress conditions.
EMBO J.
15:162-171[Medline].
|
| 25.
|
Kleerebezem, M., and J. Tommassen.
1993.
Expression of the pspA gene stimulates efficient protein export in Escherichia coli.
Mol. Microbiol.
7:947-956[CrossRef][Medline].
|
| 26.
|
Knight, A. E.
1994.
Ph.D. thesis.
Cambridge University, Cambridge, United Kingdom.
|
| 27.
|
Koski, P.,
H. Saarilahti,
S. Sukupolvi,
S. Taira,
P. Riikonen,
K. Osterlund,
R. Hurme, and M. Rhen.
1992.
A new alpha-helical coiled coil protein encoded by the Salmonella typhimurium virulence plasmid.
J. Biol. Chem.
267:12258-12265[Abstract/Free Full Text].
|
| 28.
|
Kustu, S.,
A. K. North, and D. S. Weiss.
1991.
Prokaryotic transcriptional enhancers and enhancer-binding proteins.
Trends Biochem. Sci.
16:397-402[CrossRef][Medline].
|
| 29.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 30.
|
Lee, H. S.,
F. Narberhaus, and S. Kustu.
1993.
In vitro activity of NifL, a signal transduction protein for biological nitrogen fixation.
J. Bacteriol.
175:7683-7688[Abstract/Free Full Text].
|
| 31.
|
Lee, J. H., and T. R. Hoover.
1995.
Protein crosslinking studies suggest that Rhizobium meliloti C4-dicarboxylic acid transport protein D, a sigma 54-dependent transcriptional activator, interacts with sigma 54 and the beta subunit of RNA polymerase.
Proc. Natl. Acad. Sci. USA
92:9702-9706[Abstract/Free Full Text].
|
| 32.
|
Lessl, M.,
D. Balzer,
R. Lurz,
V. L. Waters,
D. G. Guiney, and E. Lanka.
1992.
Dissection of IncP conjugative plasmid transfer: definition of the transfer region Tra2 by mobilization of the Tra1 region in trans.
J. Bacteriol.
174:2493-2500[Abstract/Free Full Text].
|
| 33.
|
Li, H. M.,
Y. Kaneko, and K. Keegstra.
1994.
Molecular cloning of a chloroplastic protein associated with both the envelope and thylakoid membranes.
Plant Mol. Biol.
25:619-632[CrossRef][Medline].
|
| 34.
|
Lupas, A.,
M. Van Dyke, and J. Stock.
1991.
Predicting coiled coils from protein sequences.
Science
252:1162-1164[Free Full Text].
|
| 35.
|
Miller, J. H.
1992.
A short course in bacterial genetics.
Cold Spring Harbor Laboratory Press, Plainview, N.Y.
|
| 36.
|
Morett, E.,
W. Cannon, and M. Buck.
1988.
The DNA-binding domain of the transcriptional activator protein NifA resides in its carboxy terminus, recognises the upstream activator sequences of nif promoters and can be separated from the positive control function of NifA.
Nucleic Acids Res.
16:11469-11488[Abstract/Free Full Text].
|
| 37.
|
Ninfa, A. J., and B. Magasanik.
1986.
Covalent modification of the glnG product, NRI, by the glnL product, NRII, regulates the transcription of the glnALG operon in Escherichia coli.
Proc. Natl. Acad. Sci. USA
83:5909-5913[Abstract/Free Full Text].
|
| 38.
|
Perez-Martin, J., and V. de Lorenzo.
1996.
ATP binding to the sigma 54-dependent activator XylR triggers a protein multimerization cycle catalyzed by UAS DNA.
Cell
86:331-339[CrossRef][Medline].
|
| 39.
|
Porath, J.
1992.
Immobilized metal ion affinity chromatography.
Protein Expr. Purif.
3:263-281[CrossRef][Medline].
|
| 40.
|
Porter, S. C.,
A. K. North,
A. B. Wedel, and S. Kustu.
1993.
Oligomerization of NTRC at the glnA enhancer is required for transcriptional activation.
Genes Dev.
7:2258-2273[Abstract/Free Full Text].
|
| 41.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 42.
|
Silhavy, T. J.,
M. L. Berman, and L. W. Enquist.
1984.
Experiments with gene fusions.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 43.
|
Simons, R. W.,
F. Houman, and N. Kleckner.
1987.
Improved single and multicopy lac-based cloning vectors for protein and operon fusions.
Gene
53:85-96[CrossRef][Medline].
|
| 44.
|
Weiner, L.,
J. L. Brissette, and P. Model.
1991.
Stress-induced expression of the Escherichia coli phage shock protein operon is dependent on sigma 54 and modulated by positive and negative feedback mechanisms.
Genes Dev.
5:1912-1923[Abstract/Free Full Text].
|
| 45.
|
Weiner, L., and P. Model.
1994.
Role of an Escherichia coli stress-response operon in stationary-phase survival.
Proc. Natl. Acad. Sci. USA
91:2191-2195[Abstract/Free Full Text].
|
| 46.
|
Winans, S. C.,
S. J. Elledge,
J. H. Krueger, and G. C. Walker.
1985.
Site-directed insertion and deletion mutagenesis with cloned fragments in Escherichia coli.
J. Bacteriol.
161:1219-1221[Abstract/Free Full Text].
|
| 47.
|
Wyman, C.,
I. Rombel,
A. K. North,
C. Bustamante, and S. Kustu.
1997.
Unusual oligomerization required for activity of NtrC, a bacterial enhancer-binding protein.
Science
275:1658-1661[Abstract/Free Full Text].
|
| 48.
|
Xiao, Y.,
S. Heu,
J. Yi,
Y. Lu, and S. W. Hutcheson.
1994.
Identification of a putative alternate sigma factor and characterization of a multicomponent regulatory cascade controlling the expression of Pseudomonas syringae pv. syringae Pss61 hrp and hrmA genes.
J. Bacteriol.
176:1025-1036[Abstract/Free Full Text].
|
Journal of Bacteriology, January 2000, p. 311-319, Vol. 182, No. 2
0021-9193/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Sheng, D., Jao, J., Li, M., Xu, P., Zhang, J.
(2009). RecX is Involved In the Switch between DNA Damage Response and Normal Metabolism in D. radiodurans. J Biochem
146: 337-342
[Abstract]
[Full Text]
-
Butcher, B. G., Lin, Y.-P., Helmann, J. D.
(2007). The yydFGHIJ Operon of Bacillus subtilis Encodes a Peptide That Induces the LiaRS Two-Component System. J. Bacteriol.
189: 8616-8625
[Abstract]
[Full Text]
-
Jordan, S., Rietkotter, E., Strauch, M. A., Kalamorz, F., Butcher, B. G., Helmann, J. D., Mascher, T.
(2007). LiaRS-dependent gene expression is embedded in transition state regulation in Bacillus subtilis. Microbiology
153: 2530-2540
[Abstract]
[Full Text]
-
Jovanovic, G., Lloyd, L. J., Stumpf, M. P. H., Mayhew, A. J., Buck, M.
(2006). Induction and Function of the Phage Shock Protein Extracytoplasmic Stress Response in Escherichia coli. J. Biol. Chem.
281: 21147-21161
[Abstract]
[Full Text]
-
Jordan, S., Junker, A., Helmann, J. D., Mascher, T.
(2006). Regulation of LiaRS-Dependent Gene Expression in Bacillus subtilis: Identification of Inhibitor Proteins, Regulator Binding Sites, and Target Genes of a Conserved Cell Envelope Stress-Sensing Two-Component System.. J. Bacteriol.
188: 5153-5166
[Abstract]
[Full Text]
-
Maxson, M. E., Darwin, A. J.
(2006). Multiple promoters control expression of the Yersinia enterocolitica phage-shock-protein A (pspA) operon.. Microbiology
152: 1001-1010
[Abstract]
[Full Text]
-
Elderkin, S., Bordes, P., Jones, S., Rappas, M., Buck, M.
(2005). Molecular Determinants for PspA-Mediated Repression of the AAA Transcriptional Activator PspF. J. Bacteriol.
187: 3238-3248
[Abstract]
[Full Text]
-
Liu, C., Willmund, F., Whitelegge, J. P., Hawat, S., Knapp, B., Lodha, M., Schroda, M.
(2005). J-Domain Protein CDJ2 and HSP70B Are a Plastidic Chaperone Pair That Interacts with Vesicle-Inducing Protein in Plastids 1. Mol. Biol. Cell
16: 1165-1177
[Abstract]
[Full Text]
-
Lloyd, L. J., Jones, S. E., Jovanovic, G., Gyaneshwar, P., Rolfe, M. D., Thompson, A., Hinton, J. C., Buck, M.
(2004). Identification of a New Member of the Phage Shock Protein Response in Escherichia coli, the Phage Shock Protein G (PspG). J. Biol. Chem.
279: 55707-55714
[Abstract]
[Full Text]
-
Aseeva, E., Ossenbuhl, F., Eichacker, L. A., Wanner, G., Soll, J., Vothknecht, U. C.
(2004). Complex Formation of Vipp1 Depends on Its {alpha}-Helical PspA-like Domain. J. Biol. Chem.
279: 35535-35541
[Abstract]
[Full Text]
-
Green, R. C., Darwin, A. J.
(2004). PspG, a New Member of the Yersinia enterocolitica Phage Shock Protein Regulon. J. Bacteriol.
186: 4910-4920
[Abstract]
[Full Text]
-
Maxson, M. E., Darwin, A. J.
(2004). Identification of Inducers of the Yersinia enterocolitica Phage Shock Protein System and Comparison to the Regulation of the RpoE and Cpx Extracytoplasmic Stress Responses. J. Bacteriol.
186: 4199-4208
[Abstract]
[Full Text]
-
Hankamer, B. D., Elderkin, S. L., Buck, M., Nield, J.
(2004). Organization of the AAA+ Adaptor Protein PspA Is an Oligomeric Ring. J. Biol. Chem.
279: 8862-8866
[Abstract]
[Full Text]
-
Marino-Ramirez, L., Minor, J. L., Reading, N., Hu, J. C.
(2004). Identification and Mapping of Self-Assembling Protein Domains Encoded by the Escherichia coli K-12 Genome by Use of {lambda} Repressor Fusions. J. Bacteriol.
186: 1311-1319
[Abstract]
[Full Text]
-
Jones, S. E., Lloyd, L. J., Tan, K. K., Buck, M.
(2003). Secretion Defects That Activate the Phage Shock Response of Escherichia coli. J. Bacteriol.
185: 6707-6711
[Abstract]
[Full Text]
-
Adams, H., Teertstra, W., Demmers, J., Boesten, R., Tommassen, J.
(2003). Interactions between Phage-Shock Proteins in Escherichia coli. J. Bacteriol.
185: 1174-1180
[Abstract]
[Full Text]
-
Lew, C. M., Gralla, J. D.
(2002). New Roles for Conserved Regions within a sigma 54-dependent Enhancer-binding Protein. J. Biol. Chem.
277: 41517-41524
[Abstract]
[Full Text]
-
Hutcheson, S. W., Bretz, J., Sussan, T., Jin, S., Pak, K.
(2001). Enhancer-Binding Proteins HrpR and HrpS Interact To Regulate hrp-Encoded Type III Protein Secretion in Pseudomonas syringae Strains. J. Bacteriol.
183: 5589-5598
[Abstract]
[Full Text]
-
Reitzer, L., Schneider, B. L.
(2001). Metabolic Context and Possible Physiological Themes of {sigma}54-Dependent Genes in Escherichia coli. Microbiol. Mol. Biol. Rev.
65: 422-444
[Abstract]
[Full Text]
-
Chaney, M., Grande, R., Wigneshweraraj, S. R., Cannon, W., Casaz, P., Gallegos, M.-T., Schumacher, J., Jones, S., Elderkin, S., Dago, A. E., Morett, E., Buck, M.
(2001). Binding of transcriptional activators to sigma 54 in the presence of the transition state analog ADP-aluminum fluoride: insights into activator mechanochemical action. Genes Dev.
15: 2282-2294
[Abstract]
[Full Text]
-
Buck, M., Gallegos, M.-T., Studholme, D. J., Guo, Y., Gralla, J. D.
(2000). The Bacterial Enhancer-Dependent sigma 54 (sigma N) Transcription Factor. J. Bacteriol.
182: 4129-4136
[Full Text]